A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)
Study of Drug in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors
Sponsor: CytomX Therapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR5081
U.S. Govt. ID: NCT03149549
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This is the first study in humans for an investigational drug called CX-2009. CX-2009 is a Probody therapeutic containing a masked antibody (an antibody is a protein naturally occurring in the human body to fight infections and in some cases tumors) attached to a maytansine derivative (a cancer killing therapy). The study is being done to look at the possible side effects, safety and tolerability of CX-2009. If you qualify for the study, you will be placed in one of 3 study parts (Part A, A2, and B). Each study part will consist of a screening period, treatment period, and follow-up period. Cancer types: breast cancer, castration-resistant prostate cancer, non-small cell lung cancer, epithelial ovarian cancer, endometrial cancer, head and neck squamous cell cancer, or cholangiocarcinoma (bile duct cancer).
This study is closed
Emerson Lim, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with one of the cancers listed in the description? Yes No
Does your cancer continue to grow? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator